home / stock / blph / blph news

BLPH News and Press, Bellerophon Therapeutics Inc. From 05/22/20

Stock Information
Company Name: Bellerophon Therapeutics Inc.
Stock Symbol: BLPH
Market: OTC
Website: bellerophon.com
Menu
BLPH BLPH Quote BLPH Short BLPH News BLPH Articles BLPH Message Board
Get BLPH Alerts

News, Short Squeeze, Breakout and More Instantly...
BLPH - Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares

WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering and concurrent registered direct offering (the “Offerings&...
BLPH - SAN, CVNA among premarket losers

Gamida Cell (NASDAQ: GMDA )  -25%  after pricing equity offering. More news on: Gamida Cell Ltd., Gossamer Bio, Inc., Bellerophon Therapeutics, Inc., Stocks on the move, , Read more ...

BLPH - Bellerophon down 13% after pricing stock offering

Bellerophon Therapeutics (NASDAQ: BLPH ) has priced its offerings for an aggregate of 3,076,923 shares of common stock at $13.00/share, for expected gross proceeds of ~$40M. More news on: Bellerophon Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

BLPH - Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of 3,076,923 shares of its common stock at a public offering price of $13.00 pe...
BLPH - Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock

WARREN, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of t...

BLPH - Bellerophon Therapeutics EPS misses by $0.07

Bellerophon Therapeutics (NASDAQ: BLPH ): Q1 GAAP EPS of -$1.08 misses by $0.07 . More news on: Bellerophon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BLPH - Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results

WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), (“Bellerophon” or the “Company”) a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today provid...
BLPH - CAH, BLUE among premarket gainers

Cellect Biotechnology (NASDAQ: APOP ) +126%  on publication of ApoGraft data ahead of clinical trial. More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., AMC Entertainment Holdings, Inc., Stocks on the move, , Read more ...

BLPH - Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19

WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announ...

BLPH - Bellerophon Therapeutics to Participate in COVID-19 Panel at Maxim Group's Infectious Disease Virtual Conference

WARREN, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer of Bellerophon, will participa...
Previous 10 Next 10